Clinical Trial: Efficacy and Safety of a Drinkable Nutraceutical for Hair Loss in Patients Using GLP-1/GIP Receptor Agonists

U.S., March 20 -- ClinicalTrials.gov registry received information related to the study (NCT07484061) titled 'Efficacy and Safety of a Drinkable Nutraceutical for Hair Loss in Patients Using GLP-1/GIP Receptor Agonists' on March 09.

Brief Summary: The purpose of this clinical trial is to evaluate the efficacy of Olistic(c) Next Women, a nutraceutical supplement, compared with placebo in improving hair loss in patients undergoing treatment with GLP-1/GIP agonists. This 6-month, randomized, placebo-controlled clinical study investigates whether daily supplementation with Olistic(c) Next Women leads to significant improvements in hair loss in this patient population. In addition, the study assesses the safety and tolerability of the product t...